Aglaia Kaissa De Boer, MD
Pulmonary Disease · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Boer’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A128593 · Current
Licensed to practise in California · since 2014 · expires 2027-03-31 · University of Ottawa School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$43,042
Medicare paid this office $43,042 for 309 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 90 | $14,495 | $121 |
| Return visit (30+ min) | 77 | $7,393 | $79 |
| New patient visit (60+ min) | 35 | $5,708 | $163 |
| Return visit (30+ min) | 22 | $3,066 | $123 |
| Long return visit (40+ min) | 17 | $2,778 | $163 |
See all 13 services
| Long return visit (40+ min) | 90 | $14,495 | $121 |
| Return visit (30+ min) | 77 | $7,393 | $79 |
| New patient visit (60+ min) | 35 | $5,708 | $163 |
| Return visit (30+ min) | 22 | $3,066 | $123 |
| Long return visit (40+ min) | 17 | $2,778 | $163 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $1,884 | $111 |
| New patient visit (45+ min) | 11 | $1,095 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,049 | $70 |
| Short return visit (20+ min) | 14 | $774 | $52 |
| Test to examine how well the lungs exchange gases | 63 | $491 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 41 | $370 | $9 |
| Test to determine lung volumes using sensors | 31 | $327 | $11 |
| Test to measure expiratory airflow and volume | 39 | $282 | $7 |
Who their Medicare patients are
309 Original Medicare patients in 2024. Average age 74 · Under 65 8% · 85 and older 10% · Women 53% · Also on Medicaid 21% · Health risk score 2.20. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 74% · Coronary heart disease 40% · COPD 34% · Diabetes 30% · Chronic kidney disease 27% · Heart failure 26% · Atrial fibrillation 26% · Cancer 21% · Depression 18% · Stroke 8% · Dementia 6%.
The office billed $146,112, Medicare allowed $57,103 and paid $43,042; for 574 services of 23 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 309 | 574 | 74 | 2.20 | $146,112 | $43,042 |
| 2023 | 318 | 527 | 74 | 1.98 | $116,052 | $36,564 |
| 2022 | 416 | 773 | 73 | 2.01 | $189,142 | $52,328 |
| 2021 | 331 | 638 | 73 | 1.94 | $116,494 | $51,324 |
| 2020 | 272 | 542 | 73 | 2.04 | $121,326 | $35,794 |
| 2019 | 130 | 223 | 72 | 1.90 | $23,669 | $11,127 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Long return visit (40+ min) | 96 | $15,188 | $126 |
| New patient visit (60+ min) | 39 | $6,388 | $164 |
| Return visit (30+ min) | 66 | $5,609 | $76 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,532 | $73 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,435 | $120 |
| Short return visit (20+ min) | 20 | $1,253 | $60 |
| Test to examine how well the lungs exchange gases | 65 | $498 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 46 | $403 | $9 |
| Test to determine lung volumes using sensors | 33 | $339 | $10 |
| Test to measure expiratory airflow and volume | 45 | $335 | $7 |
2022: 10 services
| Long return visit (40+ min) | 123 | $20,753 | $125 |
| Return visit (30+ min) | 91 | $9,222 | $77 |
| New patient visit (60+ min) | 44 | $7,669 | $174 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $2,602 | $65 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 26 | $2,292 | $88 |
| Short return visit (20+ min) | 29 | $1,505 | $52 |
| Test to examine how well the lungs exchange gases | 94 | $731 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 65 | $566 | $9 |
| Test to determine lung volumes using sensors | 48 | $479 | $10 |
| Test to measure expiratory airflow and volume | 59 | $411 | $7 |
2021: 10 services
| Long return visit (40+ min) | 94 | $18,117 | $147 |
| Return visit (30+ min) | 87 | $11,809 | $105 |
| New patient visit (60+ min) | 35 | $6,890 | $197 |
| New patient visit (45+ min) | 32 | $4,752 | $149 |
| Short return visit (20+ min) | 40 | $2,862 | $67 |
| New patient visit (30+ min) | 13 | $1,037 | $80 |
| Test to examine how well the lungs exchange gases | 80 | $644 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 49 | $449 | $9 |
| Test to measure expiratory airflow and volume | 56 | $412 | $7 |
| Test to determine lung volumes using sensors | 37 | $402 | $11 |
2020: 11 services
| Long return visit (40+ min) | 67 | $9,239 | $105 |
| Return visit (30+ min) | 69 | $6,906 | $73 |
| New patient visit (60+ min) | 45 | $6,335 | $141 |
| New patient visit (45+ min) | 25 | $2,887 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,564 | $68 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,513 | $126 |
| Short return visit (20+ min) | 19 | $907 | $48 |
| Test to examine how well the lungs exchange gases | 63 | $512 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 33 | $385 | $12 |
| Test to measure expiratory airflow and volume | 50 | $381 | $8 |
| Test to determine lung volumes using sensors | 22 | $238 | $11 |
2019: 7 services
| New patient visit (60+ min) | 27 | $4,052 | $150 |
| New patient visit (45+ min) | 22 | $2,528 | $115 |
| Long return visit (40+ min) | 15 | $1,691 | $99 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 33 | $390 | $12 |
| Test to examine how well the lungs exchange gases | 45 | $369 | $8 |
| Test to measure expiratory airflow and volume | 35 | $266 | $8 |
| Test to determine lung volumes using sensors | 23 | $256 | $11 |
Medicaid work
$77 in 2024
Medicaid paid $77 for 14 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Diffusing capacity | 14 | $77 |
| 2024 | 14 | 1 | 14 | $77 |
| 2023 | 39 | 2 | 15 | $176 |
| 2022 | 38 | 2 | 13 | $301 |
| 2021 | 26 | 2 | 14 | $181 |
See the largest Medicaid services in earlier years
2023
| Diffusing capacity | 27 | $117 |
| EVALUATION OF WHEEZING | 12 | $59 |
2022
| Diffusing capacity | 26 | $153 |
| EVALUATION OF WHEEZING | 12 | $148 |
2021
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 12 | $94 |
| Diffusing capacity | 14 | $87 |
Drugs they prescribed that Part D paid
$2,637,456
Pharmacies billed $2,637,456 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 584) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
269 generic and 315 brand-name prescriptions · $2,637,456 in drug cost · 20 antibiotic prescriptions to 13 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ofev | 205 | $2,492,220 | $12,157 |
| Pirfenidone | 47 | $86,341 | $1,837 |
| Breo Ellipta | 24 | $11,439 | $477 |
| Mycophenolate Mofetil | 83 | $6,088 | $73 |
| Albuterol Sulfate Hfa | 35 | $1,556 | $44 |
See all 10 drugs
| Ofev | 205 | $2,492,220 | $12,157 |
| Pirfenidone | 47 | $86,341 | $1,837 |
| Breo Ellipta | 24 | $11,439 | $477 |
| Mycophenolate Mofetil | 83 | $6,088 | $73 |
| Albuterol Sulfate Hfa | 35 | $1,556 | $44 |
| Azathioprine | 16 | $783 | $49 |
| Fluticasone Propionate | 28 | $267 | $10 |
| Prednisone | 25 | $216 | $9 |
| Omeprazole | 15 | $191 | $13 |
| Sulfamethoxazole-Trimethoprim | 13 | $22 | $2 |
Year by year
| 2024 | 584 | 114 | 0% (0) | 54% | $2,637,456 |
| 2023 | 528 | 92 | 0% (0) | 59% | $2,679,302 |
| 2022 | 551 | 94 | 0% (0) | 58% | $2,708,162 |
| 2021 | 595 | 90 | 0% (0) | 57% | $2,767,028 |
| 2020 | 328 | 77 | 0% (0) | 45% | $846,796 |
| 2019 | 96 | 35 | 0% (0) | 31% | $59,372 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Ofev | 191 | $2,442,266 | $12,787 |
| Pirfenidone | 48 | $154,165 | $3,212 |
| Breo Ellipta | 21 | $12,203 | $581 |
| Trelegy Ellipta | 17 | $11,878 | $699 |
| Mycophenolate Mofetil | 45 | $7,643 | $170 |
| Mycophenolic Acid | 11 | $6,195 | $563 |
| Ventolin Hfa | 19 | $1,791 | $94 |
| Albuterol Sulfate Hfa | 26 | $1,080 | $42 |
| Azathioprine | 19 | $777 | $41 |
| Omeprazole | 20 | $507 | $25 |
| Benzonatate | 11 | $311 | $28 |
| Prednisone | 16 | $170 | $11 |
2022: 12 drugs
| Ofev | 201 | $2,360,972 | $11,746 |
| Pirfenidone | 20 | $163,784 | $8,189 |
| Esbriet | 14 | $102,832 | $7,345 |
| Mycophenolate Mofetil | 61 | $20,014 | $328 |
| Breo Ellipta | 15 | $9,952 | $663 |
| Symbicort | 19 | $9,879 | $520 |
| Incruse Ellipta | 14 | $8,418 | $601 |
| Azathioprine | 23 | $1,363 | $59 |
| Albuterol Sulfate Hfa | 19 | $891 | $47 |
| Omeprazole | 24 | $233 | $10 |
| Prednisone | 26 | $231 | $9 |
| Sulfamethoxazole-Trimethoprim | 12 | $63 | $5 |
2021: 14 drugs
| Ofev | 207 | $2,377,313 | $11,485 |
| Esbriet | 31 | $309,503 | $9,984 |
| Mycophenolate Mofetil | 85 | $13,969 | $164 |
| Breo Ellipta | 17 | $9,529 | $561 |
| Spiriva | 14 | $8,174 | $584 |
| Wixela Inhub | 18 | $7,520 | $418 |
| Symbicort | 15 | $6,316 | $421 |
| Azathioprine | 22 | $961 | $44 |
| Albuterol Sulfate Hfa | 13 | $565 | $43 |
| Fluticasone Propionate | 26 | $397 | $15 |
| Pantoprazole | 12 | $385 | $32 |
| Prednisone | 31 | $264 | $9 |
| Omeprazole | 17 | $225 | $13 |
| Sulfamethoxazole-Trimethoprim | 20 | $76 | $4 |
2020: 9 drugs
| Ofev | 47 | $524,581 | $11,161 |
| Esbriet | 22 | $265,987 | $12,090 |
| Advair Diskus | 12 | $7,612 | $634 |
| Incruse Ellipta | 14 | $7,190 | $514 |
| Mycophenolate Mofetil | 58 | $5,848 | $101 |
| Fluticasone Propionate | 25 | $424 | $17 |
| Prednisone | 22 | $191 | $9 |
| Pantoprazole | 17 | $176 | $10 |
| Sulfamethoxazole-Trimethoprim | 16 | $123 | $8 |
2019: 2 drugs
| Prednisone | 14 | $235 | $17 |
| Fluticasone Propionate | 11 | $192 | $17 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1922421569
- Licence
- CA A128593California A128593: Current · expires 2027-03-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2014-02-03
- NPI last updated
- 2024-04-28
- NPI record certified
- 2024-04-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 505 Parnassus Ave, San Francisco, CA, 94143